Preclinical models suggest that DNA methyltransferase inhibitors and STING agonists may rescue the cGAS-STING pathway, allowing remodeling of the tumor microenvironment, improved anti-tumor immune responses, and more durable clinical outcomes [71,72,73]. The gene discussed is STING1; the disease is neoplasm.